Page last updated: 2024-09-03

ym 529 and mevalonic acid

ym 529 has been researched along with mevalonic acid in 3 studies

Compound Research Comparison

Studies (ym 529)	Trials (ym 529)	Recent Studies (post-2010) (ym 529)	Studies (mevalonic acid)	Trials (mevalonic acid)	Recent Studies (post-2010) (mevalonic acid)
140	23	71	3,810	33	922

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Iguchi, T; Ikeda, Y; Kizaki, M; Miyakawa, Y; Yamamoto, K	1
Fujiwara, I; Magae, J; Mizuta, M; Mizuta, N; Nakajima, H; Sakaguchi, K; Sawai, K; Tsuruga, M; Yamagishi, H	1
Aoyama, K; Kimoto, A; Minamide, T; Miyata, K; Mori, H; Mori, M; Nozaki, K; Sasamata, M; Shimizu, K; Shimokawa, K; Suzuki, H; Tanaka, M; Usui, T; Yamamotoya, H	1

Reviews

1 review(s) available for ym 529 and mevalonic acid

Article	Year
Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2009, Volume: 134, Issue:3 Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Geranyltranstransferase; GTP-Binding Proteins; Humans; Imidazoles; Mevalonic Acid; Osteoporosis; Spinal Fractures	2009

Article

Year

Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis.

Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2009, Volume: 134, Issue:3

Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Geranyltranstransferase; GTP-Binding Proteins; Humans; Imidazoles; Mevalonic Acid; Osteoporosis; Spinal Fractures

2009

Other Studies

2 other study(ies) available for ym 529 and mevalonic acid

Article	Year
Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway. Cellular signalling, 2003, Volume: 15, Issue:7 Topics: Apoptosis; Cell Division; Cell Line, Tumor; Checkpoint Kinase 1; Diphosphonates; Diterpenes; Enzyme Inhibitors; Farnesol; Humans; Imidazoles; Interleukin-6; MAP Kinase Signaling System; Mevalonic Acid; Multiple Myeloma; Phosphorylation; Protein Kinases; S Phase; Signal Transduction; Stromal Cells	2003
Induction of mitochondria-dependent apoptosis through the inhibition of mevalonate pathway in human breast cancer cells by YM529, a new third generation bisphosphonate. Cancer letters, 2007, Aug-08, Volume: 253, Issue:1 Topics: Antineoplastic Agents, Alkylating; Apoptosis; Breast Neoplasms; Diphosphonates; Drug Screening Assays, Antitumor; Humans; Imidazoles; Mevalonic Acid; Mitochondria; Polyisoprenyl Phosphates; Sesquiterpenes; Signal Transduction	2007

Article

Year

Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway.

Cellular signalling, 2003, Volume: 15, Issue:7

Topics: Apoptosis; Cell Division; Cell Line, Tumor; Checkpoint Kinase 1; Diphosphonates; Diterpenes; Enzyme Inhibitors; Farnesol; Humans; Imidazoles; Interleukin-6; MAP Kinase Signaling System; Mevalonic Acid; Multiple Myeloma; Phosphorylation; Protein Kinases; S Phase; Signal Transduction; Stromal Cells

2003

Induction of mitochondria-dependent apoptosis through the inhibition of mevalonate pathway in human breast cancer cells by YM529, a new third generation bisphosphonate.

Cancer letters, 2007, Aug-08, Volume: 253, Issue:1

Topics: Antineoplastic Agents, Alkylating; Apoptosis; Breast Neoplasms; Diphosphonates; Drug Screening Assays, Antitumor; Humans; Imidazoles; Mevalonic Acid; Mitochondria; Polyisoprenyl Phosphates; Sesquiterpenes; Signal Transduction

2007